Home › NDC Lookup › RxCUI directory › RxCUI 2047639

Sodium zirconium cyclosilicate 5000 MG Powder for Oral Suspension [Lokelma] — RxCUI 2047639

RxNorm drug concept · Semantic branded drug
RxCUI 2047639 Semantic branded drug · SBD ● Current RxNorm concept 3 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2047639
Official nameSodium zirconium cyclosilicate 5000 MG Powder for Oral Suspension [Lokelma]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asLokelma 5 GM Powder for Oral Suspension; Lokelma 5000 MG Powder for Oral Suspension
FDA products mapped3
Package NDCs mapped6
Reported Medicaid activity (SDUD)70,530 prescriptions · 50 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Sodium Zirconium Cyclosilicate: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats hyperkalemia, which means high potassium in your blood, in adults. It is not for emergencies, because it works too slowly for life-threatening high potassium.
  • Pour the whole packet into a glass with about 3 tablespoons of water, stir and drink right away. If powder is left, add water and drink again until it is gone. Follow your prescrib...
  • In general, take other oral medicines at least 2 hours before or 2 hours after Lokelma. It can change how some drugs are absorbed. Ask me or your prescriber if you are unsure about...
  • The most common one is swelling (edema), usually mild to moderate. It is more likely at higher daily amounts. Call your doctor if swelling gets worse, especially if you have heart...
📖 Read our full Sodium Zirconium Cyclosilicate guide →

🕸️ Concept Web — How Sodium zirconium cyclosilicate 5000 MG Powder fo... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Sodium zirconium cyclosilicate 5000 MG Powder for Oral Suspension [Lokelma] RxCUI 2047639

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Sodium zirconium cyclosilicate 2047628
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Lokelma 2047634
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Sodium zirconium cyclosilicate Powder for Oral Suspension 2047632
    • Sodium zirconium cyclosilicate Oral Powder Product 2047630
    • Sodium zirconium cyclosilicate Oral Product 2047631
    • Sodium zirconium cyclosilicate Powder for Oral Suspension [Lokelma] 2047636
    • Lokelma Oral Powder Product 2047637
    • Lokelma Oral Product 2047638
    • Powder for Oral Suspension 1540456
    • Oral Powder Product 1294711
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Sodium zirconium cyclosilicate 5000 MG Powder for Oral Suspension SCD · 2047633
  • Sodium zirconium cyclosilicate 5000 MG SCDC · 2047629
  • Sodium zirconium cyclosilicate Powder for Oral Suspension SCDF · 2047632
  • Sodium zirconium cyclosilicate Oral Powder Product SCDG · 2047630
  • Sodium zirconium cyclosilicate Oral Product SCDG · 2047631

Brand-Name Concepts

  • Sodium zirconium cyclosilicate 5000 MG [Lokelma] SBDC · 2047635
  • Sodium zirconium cyclosilicate Powder for Oral Suspension [Lokelma] SBDF · 2047636
  • Lokelma Oral Powder Product SBDG · 2047637
  • Lokelma Oral Product SBDG · 2047638
  • Lokelma BN · 2047634

📦 FDA Products & Package NDCs

3 products · 6 package NDCs
6 package NDCs map to RxCUI 2047639 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00310-1105-30 30 PACKET in 1 BOX (0310-1105-30) / 5 g in 1 PACKET (0310-1... LOKELMA AstraZeneca Pharmaceuticals LP 2018-09-04
00310-1105-39 11 PACKET in 1 BOX (0310-1105-39) / 5 g in 1 PACKET (0310-1... LOKELMA AstraZeneca Pharmaceuticals LP 2019-01-02
00310-1110-30 30 PACKET in 1 BOX (0310-1110-30) / 10 g in 1 PACKET (0310-... LOKELMA AstraZeneca Pharmaceuticals LP 2018-09-04
00310-1110-39 11 PACKET in 1 BOX (0310-1110-39) / 10 g in 1 PACKET (0310-... LOKELMA AstraZeneca Pharmaceuticals LP 2019-01-02
00310-1110-93 3 PACKET in 1 BOX (0310-1110-93) / 10 g in 1 PACKET (0310-1... LOKELMA AstraZeneca Pharmaceuticals LP 2024-02-01
50090-6502-00 30 PACKET in 1 BOX (50090-6502-0) / 5 g in 1 PACKET LOKELMA A-S Medication Solutions 2023-05-25
Observed labelers: AstraZeneca Pharmaceuticals LP (5) · A-S Medication Solutions (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.